As of 2025-05-23, the Relative Valuation of Nektar Therapeutics (NKTR) is (12.06) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.66 USD, the upside of Nektar Therapeutics based on Relative Valuation is -1926.7%.
The range of the Relative Valuation is (11.59) - (11.70) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.7x - 16.9x | 16.8x |
| Forward P/E multiples | 16.8x - 18.7x | 18.0x |
| Fair Price | (11.59) - (11.70) | (12.06) |
| Upside | -1856.6% - -1873.4% | -1926.7% |
| Date | P/E |
| 2025-05-22 | -0.96 |
| 2025-05-21 | -0.92 |
| 2025-05-20 | -0.99 |
| 2025-05-19 | -1.01 |
| 2025-05-16 | -0.99 |
| 2025-05-15 | -0.98 |
| 2025-05-14 | -1.03 |
| 2025-05-13 | -1.03 |
| 2025-05-12 | -1.03 |
| 2025-05-09 | -0.85 |
| 2025-05-08 | -0.90 |
| 2025-05-07 | -0.88 |
| 2025-05-06 | -0.93 |
| 2025-05-05 | -0.99 |
| 2025-05-02 | -1.09 |
| 2025-05-01 | -1.13 |
| 2025-04-30 | -1.15 |
| 2025-04-29 | -1.07 |
| 2025-04-28 | -1.09 |
| 2025-04-25 | -1.12 |
| 2025-04-24 | -1.07 |
| 2025-04-23 | -0.99 |
| 2025-04-22 | -0.96 |
| 2025-04-21 | -0.91 |
| 2025-04-17 | -0.92 |
| 2025-04-16 | -0.88 |
| 2025-04-15 | -0.92 |
| 2025-04-14 | -0.87 |
| 2025-04-11 | -0.89 |
| 2025-04-10 | -0.72 |
| 2025-04-09 | -0.74 |
| 2025-04-08 | -0.71 |
| 2025-04-07 | -0.71 |
| 2025-04-04 | -0.80 |
| 2025-04-03 | -0.87 |
| 2025-04-02 | -0.95 |
| 2025-04-01 | -0.92 |
| 2025-03-31 | -0.98 |
| 2025-03-28 | -1.07 |
| 2025-03-27 | -1.10 |
| 2025-03-26 | -1.16 |
| 2025-03-25 | -1.21 |
| 2025-03-24 | -1.25 |
| 2025-03-21 | -1.25 |
| 2025-03-20 | -1.26 |
| 2025-03-19 | -1.30 |
| 2025-03-18 | -1.27 |
| 2025-03-17 | -1.32 |
| 2025-03-14 | -1.30 |
| 2025-03-13 | -1.18 |